Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H van der Zee

Showing results (81-90 of 174) with videos related to

Pageof 18
Sort By:
The British Journal of Dermatology|October 22, 2011
Adalimumab (antitumour necrosis factor-α) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo studyH H van der Zee, J D Laman, L de Ruiter, et al.
Journal of the American Academy of Dermatology|June 2, 2014
Hidradenitis suppurativa: a retrospective study of 846 Dutch patients to identify factors associated with disease severityAnne M R Schrader, Inge E Deckers, Hessel H van der Zee, et al.
The British Journal of Dermatology|January 19, 2019
The anti-inflammatory potency of biologics targeting tumour necrosis factor-α, interleukin (IL)-17A, IL-12/23 and CD20 in hidradenitis suppurativa: an ex vivo studyA R J V Vossen, C B Ardon, H H van der Zee, et al.
Journal of the American Academy of Dermatology|November 29, 2018
Apremilast for moderate hidradenitis suppurativa: Results of a randomized controlled trialAllard R J V Vossen, Martijn B A van Doorn, Hessel H van der Zee, et al.
The Journal of Dermatology|September 9, 2016
Hidradenitis suppurativa is not associated with the metabolic syndrome based on body type: A cross-sectional studyAllard R J V Vossen, Hessel H van der Zee, Armanda J Onderdijk, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 19, 2023
Improved clinical effectiveness of adalimumab when initiated with clindamycin and rifampicin in hidradenitis suppurativaP Aarts, J C van Huijstee, H H van der Zee, et al.
Thrombosis Research|February 15, 1990
Platelet activating factor and sheep platelets: a sensitive new bioassayD G Moon, H van der Zee, K D Morton, et al.
Topics in Stroke Rehabilitation|January 24, 2013
Participation in the chronic phase of strokeCarlijn H van der Zee, Johanna M A Visser-Meily, Eline Lindeman, et al.
Journal of the American Academy of Dermatology|September 6, 2020
Long-term treatment with apremilast in hidradenitis suppurativa: A 2-year follow-up of initial respondersPim Aarts, Allard R J V Vossen, Hessel H van der Zee, et al.
American Journal of Clinical Dermatology|April 22, 2017
Assessing Pruritus in Hidradenitis Suppurativa: A Cross-Sectional StudyAllard R J V Vossen, Annelien Schoenmakers, Kelsey R van Straalen, et al.
Pageof 18

Showing results (81-90 of 174) with videos related to

Sort By:
Pageof 18
The British Journal of Dermatology|October 22, 2011
Adalimumab (antitumour necrosis factor-α) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo studyH H van der Zee, J D Laman, L de Ruiter, et al.
Journal of the American Academy of Dermatology|June 2, 2014
Hidradenitis suppurativa: a retrospective study of 846 Dutch patients to identify factors associated with disease severityAnne M R Schrader, Inge E Deckers, Hessel H van der Zee, et al.
The British Journal of Dermatology|January 19, 2019
The anti-inflammatory potency of biologics targeting tumour necrosis factor-α, interleukin (IL)-17A, IL-12/23 and CD20 in hidradenitis suppurativa: an ex vivo studyA R J V Vossen, C B Ardon, H H van der Zee, et al.
Journal of the American Academy of Dermatology|November 29, 2018
Apremilast for moderate hidradenitis suppurativa: Results of a randomized controlled trialAllard R J V Vossen, Martijn B A van Doorn, Hessel H van der Zee, et al.
The Journal of Dermatology|September 9, 2016
Hidradenitis suppurativa is not associated with the metabolic syndrome based on body type: A cross-sectional studyAllard R J V Vossen, Hessel H van der Zee, Armanda J Onderdijk, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 19, 2023
Improved clinical effectiveness of adalimumab when initiated with clindamycin and rifampicin in hidradenitis suppurativaP Aarts, J C van Huijstee, H H van der Zee, et al.
Thrombosis Research|February 15, 1990
Platelet activating factor and sheep platelets: a sensitive new bioassayD G Moon, H van der Zee, K D Morton, et al.
Topics in Stroke Rehabilitation|January 24, 2013
Participation in the chronic phase of strokeCarlijn H van der Zee, Johanna M A Visser-Meily, Eline Lindeman, et al.
Journal of the American Academy of Dermatology|September 6, 2020
Long-term treatment with apremilast in hidradenitis suppurativa: A 2-year follow-up of initial respondersPim Aarts, Allard R J V Vossen, Hessel H van der Zee, et al.
American Journal of Clinical Dermatology|April 22, 2017
Assessing Pruritus in Hidradenitis Suppurativa: A Cross-Sectional StudyAllard R J V Vossen, Annelien Schoenmakers, Kelsey R van Straalen, et al.
Pageof 18